Systemic antigen in the treatment of T-cell-mediated autoimmune diseases.
Systemic injection of antigen is one of the approaches that reproducibly induces effective antigen-specific hyporesponsiveness. Here, Roland Liblau and colleagues discuss the cellular and molecular bases of such tolerance, review the current use of this therapeutic strategy in experimental organ-specific autoimmune diseases and analyse what steps are necessary to make this approach suitable for clinical use.
Liblau
R
R
Cellular Immunology Laboratory, Hôpital Salpêtrière, Paris, France. 106063.1005@compuserve.com
Tisch
R
R
Bercovici
N
N
McDevitt
H O
HO
D000818:Animals; D000941:Antigens / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology* / Q000628:therapy*; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D008212:Lymphocyte Depletion; D051379:Mice; D016688:Mice, Inbred NOD; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000276:immunology*
D000941:Antigens